Home Overview Press Room Blog Publications For Students about us
Search

About Race & Human Biotechnology


Racist ideas and practices have marred the history of science, with low points including the eugenics movement and medical experiments on vulnerable populations. Public awareness and social oversight are needed to ensure that these sorts of occurrences are not repeated.

Today, some geneticists and biomedical researchers are searching for genetic differences between racial groups, raising concerns that these biological variations may be used to justify inequitable outcomes that are created by social, environmental, and economic forces. However well-meaning, this could lead to gross abuse.

Genetic researchers have been particularly interested in indigenous peoples. Their reproductive insularity has led to a genetic homogeneity that can facilitate searches for correlations between specific genes and phenotypic traits. Many indigenous people object to this work for a variety of practical and ethical reasons, including the patenting and commercialization of genetic information, the lack of fully informed consent, the potential for genetic discrimination, and the disproportionate allocation of public funds to genetic research rather than to direct health care and prevention programs.



The Race Card in Michiganby Osagie ObasogieBiopolitical TimesNovember 3rd, 2008Opponents of Proposal 2 tend to view embryos as an early form of human life and therefore see embryonic stem cell research as unethical human experimentation. To bolster their moral claim regarding the use of vulnerable subjects in scientific research, they are now comparing embryonic stem cell research to the Tuskegee experiment.
NitroMed Sells Off Its Only Product, a Controversial Heart Pill for African Americansby Rebecca ZacksXconomyOctober 23rd, 2008Nine months after slashing its staff and discontinuing marketing of its only marketed product - a heart-failure drug approved specifically for African Americans - NitroMed is selling all the assets related to the pill.
How the (Not so) Mighty Have Fallenby Osagie Obasogie Biopolitical TimesOctober 2nd, 2008Just three years ago, NitroMed (makers of BiDil, the first FDA-approved race specific medicine) was heralded as a promising pharmaceutical company with a business model for BiDil that led some analysts to predict sales of between $500 million and $1 billion by 2010. Yet, BiDil’s fortunes have swung drastically in the other direction
Beyond Best Practices [PDF]Strict Scrutiny as a Regulatory Model for Race-Specific Medicinesby Osagie K. ObasogieJournal of Law, Medicine, and Ethics (Fall 2008)Given the vigorous and unsettled debate concerning the genetic relevance of race, the state has a strong interest in approving the use of race-specific indications only when they are used cautiously, are supported by robust scientific studies, and are not simply used as a convenient proxy.
The Ethics of Characterizing Difference: Guiding Principles on Using Racial Categories in Human Geneticsby Sandra Soo-Jin Lee et. al. Genome BiologyJuly 15th, 2008A multidisciplinary group of Stanford University faculty members propose ten principles to guide the use of racial and ethnic categories when characterizing group differences in research into human genetic variation.
Gene of the Week: American Exceptionalismby Jesse ReynoldsBiopolitical TimesJune 20th, 2008Conservative pundit Michael Medved recently offered a genetic antidote to white guilt.
Henry Louis Gates Jr. Interviews James Watsonby Osagie ObasogieBiopolitical TimesJune 9th, 2008Race scholar Henry Louis Gates Jr., who has filmed two documentaries on race, genetics, and ancestry while also founding a DNA ancestry company, was troubled by Watson’s seemingly pernicious use of race and genetics....This led Gates to interview Watson to, in a sense, determine whether he’s a bigot.
Conceiving the Future [PDF]Reproductive-justice activists on technology and policyby Andi Zeisler and Emily GalpernBitchJune 6th, 2008Emerging reproductive and genetic technologies have raised critical issues for social-justice movements. This roundtable discussion features some of the women who've been engaged in these national conversations.
Race-specific drugs: regulatory trends and public policyby David E. Winickoff and Osagie K. ObasogieTrends in Pharmacological SciencesJune 4th, 2008The need for new regulatory approaches to medicines with race-specific indications is growing more acute.
Heart Drug's Racial Focus Proves a Liability Rather Than an Assetby Angela StewartThe Star-LedgerMay 31st, 2008After three years on the market, BiDil has failed to live up to predictions by analysts of $100 million in annual sales. Some would even argue it has been a flop.
Displaying 1-10 of 65  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 436 14th Street Suite 700, Oakland CA 94612 USA • • (p) 1.510.625.0819 • (F) 1.510.625.0874